As your CRO we can help you in the preclinal development process. We know that your compounds are unique and valuable, that is why we at Aquilo take a customized approach.
Our focus lies in defining the impact of your compounds on characteristics of asthma, COPD and/or lung fibrosis. An approach may include 2D and 3D in vitro, in vivo and ex vivo models.
For efficacy studies Aquilo offers a range of in vivo models. For example for asthma, we have acute and chronic models, for which we can use both mice and guinea pigs.
Furthermore, we offer relevant COPD and lung fibrosis models.
